Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with C

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
331 Q3 2021 CITRIC ACID MONOHYDRATE BUCCAL FILM, SOLUBLE 0.69 mg Correction
969 Q3 2021 CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL GEL, METERED 0.90 %w/w MDE Replacement
969 Q4 2021 CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL GEL, METERED 31.5 mg MDE Replacement
979 Q3 2021 CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL GEL 0.85 %w/w MDE Replacement
979 Q4 2021 CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL GEL 8.4 mg MDE Replacement
984 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL CAPSULE 20.00 mg MDE Replacement
984 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL CAPSULE 40 mg MDE Replacement
985 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL GRANULE, FOR SUSPENSION 150.00 mg/ 5.00 ml MDE Replacement
985 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL GRANULE, FOR SUSPENSION 600 mg MDE Replacement
1000 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL SUSPENSION 50.00 mg/ 5.00 ml MDE Replacement
1000 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL SUSPENSION 288 mg MDE Replacement
1001 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, EXTENDED RELEASE 90.00 mg MDE Replacement
1001 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, EXTENDED RELEASE 90 mg MDE Replacement
1002 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, FILM COATED, EXTENDED RELEASE 3.00 mg MDE Replacement
1002 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, FILM COATED, EXTENDED RELEASE 9 mg MDE Replacement
1003 Q3 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, ORALLY DISINTEGRATING 0.30 mg MDE Replacement
1003 Q4 2021 CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) ORAL TABLET, ORALLY DISINTEGRATING 1.2 mg MDE Replacement
1016 Q3 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL CREAM, AUGMENTED 1.00 %w/w MDE Replacement
1016 Q4 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL CREAM, AUGMENTED 20 mg MDE Replacement
1017 Q3 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL EMULSION 0.60 %w/w MDE Replacement
1017 Q4 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL EMULSION 6 mg MDE Replacement
1019 Q3 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL LOTION 0.50 %w/w MDE Replacement
1019 Q4 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL LOTION 20 mg MDE Replacement
1020 Q3 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL OINTMENT, AUGMENTED 2.25 %w/w MDE Replacement
1020 Q4 2021 CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) TOPICAL OINTMENT, AUGMENTED 22.5 mg MDE Replacement
1039 Q3 2021 CARBOXYMETHYLCELLULOSE SODIUM BUCCAL FILM 17.64 mg MDE Replacement
1039 Q4 2021 CARBOXYMETHYLCELLULOSE SODIUM BUCCAL FILM 17.64 mg MDE Replacement
1041 Q3 2021 CARBOXYMETHYLCELLULOSE SODIUM BUCCAL FILM, SOLUBLE 10.95 mg MDE Replacement
1041 Q4 2021 CARBOXYMETHYLCELLULOSE SODIUM BUCCAL FILM, SOLUBLE 44 mg MDE Replacement
1067 Q3 2021 CARBOXYMETHYLCELLULOSE SODIUM ORAL SOLUTION 35.00 mg/ 1.00 ml MDE Replacement
1067 Q4 2021 CARBOXYMETHYLCELLULOSE SODIUM ORAL SOLUTION 1080 mg MDE Replacement
1125 Q3 2021 CASTOR OIL ORAL CAPSULE, EXTENDED RELEASE 1.76 mg MDE Replacement
1125 Q4 2021 CASTOR OIL ORAL CAPSULE, EXTENDED RELEASE 22 mg MDE Replacement
1127 Q3 2021 CASTOR OIL ORAL TABLET 2.00 mg MDE Replacement
1127 Q4 2021 CASTOR OIL ORAL TABLET 16.8175 mg MDE Replacement
1154 Q3 2021 CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM NASAL SPRAY, METERED 20.00 mg MDE Replacement
1154 Q4 2021 CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM NASAL SPRAY, METERED 60 mg MDE Replacement
1169 Q3 2021 CERESIN VAGINAL CREAM 7.00 %w/w MDE Replacement
1169 Q4 2021 CERESIN VAGINAL CREAM 280 mg MDE Replacement
Q3 2021 CROSCARMELLOSE SODIUM ORAL TABLET, FILM COATED 165.00 mg MDE Replacement
Q4 2021 CROSCARMELLOSE SODIUM ORAL TABLET, FILM COATED 330 mg MDE Replacement
1523 Q3 2021 CROSCARMELLOSE SODIUM ORAL TABLET, FOR SUSPENSION 30.00 mg MDE Replacement
1523 Q4 2021 CROSCARMELLOSE SODIUM ORAL TABLET, FOR SUSPENSION 46.4 mg MDE Replacement
1541 Q3 2021 CROSPOVIDONE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 60.00 mg MDE Replacement
1541 Q4 2021 CROSPOVIDONE ORAL TABLET, CHEWABLE, EXTENDED RELEASE 90 mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: September 30, 2021
Database Last Updated: October 21, 2021

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English